An Important Question
What options are there for stage 4 non-small cell lung cancer patients with limited metastatic disease – the cancer has spread to less than 3 organs other than the lung?
Study after study have shown that most failures of chemotherapy are exactly at the places of the original lung cancer, and not new sites. So why not focus on those areas instead of giving more “maintenance” chemotherapy?
An Important Clinical Trial
Dr. Daniel Gomez and colleagues spearheaded a clinical trial (ClinicalTrials.gov space NCT01725165) that randomly assigned stage 4 lung patients to “maintenance” chemotherapy versus local therapy (mostly radiation, but some with surgery) versus no treatment at all.
The multi-center study was published in the British journal called The Lancet Oncology in December 2016, pages 1672-1682. To be eligible for the clinical trial, stage 4 non-small cell lung cancer patients had standard chemotherapy and were in relatively good shape after chemotherapy treatment.
A Breakthrough Result
Although only 74 lung cancer patients were entered into the clinical trial from 2012 to 2016, a real breakthrough result was seen. The breakthrough result was that the local therapy group (radiation or surgery) survived 12 months versus 4 months for the “maintenance” chemotherapy group. The clinical trial was closed early because the doctors saw better results in the local therapy group (radiation or surgery) versus the “maintenance” chemotherapy group.
Where Do You Go from Here?
As a CyberKnife cancer specialist in Dayton Ohio, CyberKnife offers our stage 4 non-small cell lung cancer patients real hope. And CyberKnife can help you beat your non-small cell lung cancer without surgery. No pain and no incisions. Real hope for another year of symptom free survival.
If you have any questions about your lung cancer, please feel free to call me, Dr. Edward Hughes at 855-Dayton 1. Or visit our website and I guarantee that I will see you within 1-3 days of your phone call.